Literature DB >> 25738163

Disease exacerbation after rituximab induction in neuromyelitis optica.

Jai S Perumal1, Ilya Kister1, Jonathan Howard1, Joseph Herbert1.   

Abstract

Entities:  

Year:  2015        PMID： 25738163      PMCID： PMC4335814          DOI： 10.1212/NXI.0000000000000061

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN： 2332-7812


× No keyword cloud information.
  7 in total

1.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.

Authors:  Chun-Sheng Yang; Li Yang; Ting Li; Da-Qi Zhang; Wei-Na Jin; Min-Shu Li; Ning Su; Nannan Zhangning; Qiang Liu; Zong-Hong Shao; Chunshui Yu; Fu-Dong Shi
Journal:  Neurology       Date:  2013-07-24       Impact factor: 9.910

2.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Authors:  H L Pellkofer; M Krumbholz; A Berthele; B Hemmer; L A Gerdes; J Havla; R Bittner; M Canis; E Meinl; R Hohlfeld; T Kuempfel
Journal:  Neurology       Date:  2011-04-12       Impact factor: 9.910

Review 3.  A review of cases of neuromyelitis optica.

Authors:  Roberto Bomprezzi; Eugene Postevka; Denise Campagnolo; Timothy L Vollmer
Journal:  Neurologist       Date:  2011-03       Impact factor: 1.398

4.  Impact of rituximab on relapse rate and disability in neuromyelitis optica.

Authors:  Gurdesh S Bedi; Andrew D Brown; Sylvia R Delgado; Nida Usmani; Byron L Lam; William A Sheremata
Journal:  Mult Scler       Date:  2011-05-26       Impact factor: 6.312

5.  An open label study of the effects of rituximab in neuromyelitis optica.

Authors:  B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.

Authors:  Vincent H L Ip; Alexander Y L Lau; Lisa W C Au; Florence S Y Fan; Anne Y Y Chan; Vincent C T Mok; Ka-Sing Lawrence Wong
Journal:  J Neurol Sci       Date:  2012-10-02       Impact factor: 3.181

7.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08
  7 in total
  13 in total

1.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 3.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 4.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 5.  Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.

Authors:  Hesham Abboud; John Probasco; Sarosh R Irani; Beau Ances; David R Benavides; Michael Bradshaw; Paulo Pereira Christo; Russell C Dale; Mireya Fernandez-Fournier; Eoin P Flanagan; Avi Gadoth; Pravin George; Elena Grebenciucova; Adham Jammoul; Soon-Tae Lee; Yuebing Li; Marcelo Matiello; Anne Marie Morse; Alexander Rae-Grant; Galeno Rojas; Ian Rossman; Sarah Schmitt; Arun Venkatesan; Steven Vernino; Sean J Pittock; Maarten Titulaer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-03-01       Impact factor: 13.654

Review 6.  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.

Authors:  Laura Cacciaguerra; Paola Tortorella; Maria A Rocca; Massimo Filippi
Journal:  Neurotherapeutics       Date:  2021-04-28       Impact factor: 6.088

7.  Observations on the evolving fields of neuroimmunology and neuroinflammation.

Authors:  Josep Dalmau
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-05

8.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

9.  Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.

Authors:  Christine Lebrun; Mikael Cohen; Maria Alessandra Rosenthal-Allieri; Saskia Bresch; Sylvia Benzaken; Romain Marignier; Barbara Seitz-Polski; Michel Ticchioni
Journal:  Neurol Ther       Date:  2018-06-07

10.  Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.

Authors:  Daniel H Whittam; Alvaro Cobo-Calvo; A Sebastian Lopez-Chiriboga; Santiago Pardo; Matthew Gornall; Silvia Cicconi; Alexander Brandt; Klaus Berek; Thomas Berger; Ilijas Jelcic; Grace Gombolay; Luana Micheli Oliveira; Dagoberto Callegaro; Kimihiko Kaneko; Tatsuro Misu; Marco Capobianco; Emily Gibbons; Venkatraman Karthikeayan; Bruno Brochet; Bertrand Audoin; Guillaume Mathey; David Laplaud; Eric Thouvenot; Mikaël Cohen; Ayman Tourbah; Elisabeth Maillart; Jonathan Ciron; Romain Deschamps; Damien Biotti; Kevin Rostasy; Rinze Neuteboom; Cheryl Hemingway; Rob Forsyth; Marcelo Matiello; Stewart Webb; David Hunt; Katy Murray; Yael Hacohen; Ming Lim; M Isabel Leite; Jacqueline Palace; Tom Solomon; Andreas Lutterotti; Kazuo Fujihara; Ichiro Nakashima; Jeffrey L Bennett; Lekha Pandit; Tanuja Chitnis; Brian G Weinshenker; Brigitte Wildemann; Douglas Kazutoshi Sato; Su-Hyun Kim; Saif Huda; Ho Jin Kim; Markus Reindl; Michael Levy; Sven Jarius; Silvia Tenembaum; Friedemann Paul; Sean Pittock; Romain Marignier; Anu Jacob
Journal:  Mult Scler Relat Disord       Date:  2020-06-02       Impact factor: 4.339
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.